In the British Journal of Cancer this week, researchers in Italy present the results of the ROSORC trial that tested sorafenib with interleukin-2 therapy versus sorafenib alone in patients with metastatic renal cell carcinoma. In this phase II study, 128 patients were randomized to receive sorafenib alone or with subcutaneous IL-2. After a median follow-up of 27 months, median progression-free survival was only 33 weeks with the combination therapy, compared with 30 weeks for monotherapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.